Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine.

The company has two trading businesses: Genomic Solutions comprises of CytoSure cytogenetics array, labeling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency Genomics, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data.

The Biomarkers business utilizes proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programs in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.